61 results
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
14 May 24
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
7:45am
safety, pharmacokinetic and pharmacodynamic data for XTX301 in patients with advanced solid tumors in the fourth quarter of 2024.
Tumor-activated … clinical trial. Xilio is currently evaluating the safety and tolerability of the combination in patients with advanced solid tumors in the Phase 1 dose
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
1 Apr 24
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4:15pm
.
In January 2024, Xilio reported encouraging preliminary safety data into the third dose level in the ongoing Phase 1 clinical trial. As of the data … human IL-12, and was generally well-tolerated with no dose-limiting toxicities observed.
Xilio today reaffirmed plans to report Phase 1 safety
8-K
EX-99.2
v3zkbe
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.1
ol6gr0gjmy5 gg0psb60
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-10.1
m64o0ztwb5r 5khq4
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.1
hf4m52udoffbo ecwp
7 Dec 23
Other Events
7:45am
8-K
mdaqpbe5wcr3zh188r
7 Dec 23
Other Events
7:45am
8-K
EX-99.1
f6qkaa5ccjwpgpis
9 Nov 23
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
4:13pm
8-K
lgf1 ag51k4
3 Nov 23
Other Events
4:05pm
8-K
EX-99.1
mkh8l llu7kkw0y
3 Nov 23
Other Events
4:05pm
8-K
EX-99.1
qdjx5 mi64rf3rbml0n
5 Sep 23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
8:35am
8-K
EX-99.1
hrm1s j3s6bv
14 Aug 23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
7:40am
8-K
EX-99.2
pd5m4blp98l06
14 Aug 23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
7:40am
8-K
lihvz9g
25 May 23
Regulation FD Disclosure
5:05pm